$IMUX
Immunic Inc

2016 Q2 Form 10-Q Financial Statement

#000162828016015949 Filed on May 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.690M $2.800M $3.060M
YoY Change -23.8% -8.5% 15.04%
% of Gross Profit
Research & Development $6.858M $6.857M $11.75M
YoY Change -40.6% -41.66% 27.49%
% of Gross Profit
Depreciation & Amortization $490.0K $494.0K $294.0K
YoY Change 49.39% 68.03% -1.01%
% of Gross Profit
Operating Expenses $9.546M $9.656M $14.82M
YoY Change -36.69% -34.83% 24.76%
Operating Profit -$9.546M -$9.656M -$14.82M
YoY Change -36.69% -34.83% 24.76%
Interest Expense $80.00K $60.00K $10.00K
YoY Change 700.0% 500.0%
% of Operating Profit
Other Income/Expense, Net $78.00K $67.00K $59.00K
YoY Change -378.57% 13.56% -94.77%
Pretax Income -$9.470M -$9.590M -$14.76M
YoY Change -37.33% -35.03% 37.3%
Income Tax
% Of Pretax Income
Net Earnings -$9.468M -$9.589M -$14.76M
YoY Change -37.32% -35.03% 37.31%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$12.14M -$12.62M -$24.60M
COMMON SHARES
Basic Shares Outstanding 31.24M shares 30.47M shares 23.99M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.60M $77.90M $88.30M
YoY Change 2.36% -11.78% 91.96%
Cash & Equivalents $73.60M $77.88M $88.26M
Short-Term Investments
Other Short-Term Assets $1.800M $1.300M $2.300M
YoY Change -48.57% -43.48% -62.9%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $75.44M $79.24M $90.62M
YoY Change -0.01% -12.56% 73.39%
LONG-TERM ASSETS
Property, Plant & Equipment $3.014M $3.428M $4.108M
YoY Change -28.44% -16.55% 33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $182.0K $253.0K $198.0K
YoY Change -14.95% 27.78% -24.71%
Total Long-Term Assets $3.196M $3.681M $4.306M
YoY Change -27.79% -14.51% 28.77%
TOTAL ASSETS
Total Short-Term Assets $75.44M $79.24M $90.62M
Total Long-Term Assets $3.196M $3.681M $4.306M
Total Assets $78.63M $82.92M $94.92M
YoY Change -1.55% -12.65% 70.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $887.0K $885.0K $1.128M
YoY Change -3.59% -21.54% -14.87%
Accrued Expenses $3.439M $3.788M $9.591M
YoY Change -61.15% -60.5% 74.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.473M $4.816M $10.95M
YoY Change -55.17% -56.0% 26.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $100.0K $200.0K
YoY Change -100.0% -50.0% -28.32%
Total Long-Term Liabilities $12.00K $56.00K $200.0K
YoY Change -92.45% -72.0% -28.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.473M $4.816M $10.95M
Total Long-Term Liabilities $12.00K $56.00K $200.0K
Total Liabilities $4.485M $4.872M $11.15M
YoY Change -55.75% -56.29% 25.07%
SHAREHOLDERS EQUITY
Retained Earnings -$221.9M -$212.4M -$165.6M
YoY Change 22.81% 28.3%
Common Stock $56.00K $56.00K $2.000K
YoY Change 2700.0% 2700.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.15M $78.05M $83.78M
YoY Change
Total Liabilities & Shareholders Equity $78.63M $82.92M $94.92M
YoY Change -1.55% -12.65% 70.7%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$9.468M -$9.589M -$14.76M
YoY Change -37.32% -35.03% 37.31%
Depreciation, Depletion And Amortization $490.0K $494.0K $294.0K
YoY Change 49.39% 68.03% -1.01%
Cash From Operating Activities -$8.820M -$9.960M -$13.51M
YoY Change -41.63% -26.28% 44.34%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $125.0K $674.0K
YoY Change -96.95% -81.45% -16.69%
Acquisitions
YoY Change
Other Investing Activities $80.00K $220.0K $60.00K
YoY Change -33.33% 266.67% -250.0%
Cash From Investing Activities $40.00K $90.00K -$620.0K
YoY Change -103.36% -114.52% -27.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.325M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.510M 4.330M 140.0K
YoY Change 2992.86% -99.23%
NET CHANGE
Cash From Operating Activities -8.820M -9.960M -13.51M
Cash From Investing Activities 40.00K 90.00K -620.0K
Cash From Financing Activities 4.510M 4.330M 140.0K
Net Change In Cash -4.270M -5.540M -13.99M
YoY Change -73.8% -60.4% -277.99%
FREE CASH FLOW
Cash From Operating Activities -$8.820M -$9.960M -$13.51M
Capital Expenditures -$40.00K $125.0K $674.0K
Free Cash Flow -$8.780M -$10.09M -$14.18M
YoY Change -36.38% -28.9% 39.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1221000 USD
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
885000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5271000 USD
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3788000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8060000 USD
CY2016Q1 us-gaap Assets
Assets
82920000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
85088000 USD
CY2016Q1 us-gaap Assets Current
AssetsCurrent
79239000 USD
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
934000 USD
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31244415 shares
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
CY2016Q1 dei Trading Symbol
TradingSymbol
VTL
CY2016Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8499000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000 USD
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
285098000 USD
CY2016Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
290409000 USD
CY2015Q4 us-gaap Assets
Assets
89081000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102238000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88257000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83416000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77876000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13981000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5540000 USD
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250646 shares
CY2016Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250539 shares
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4329736 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30473083 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30980181 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30473083 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30980181 shares
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14757000 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
14817000 USD
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9589000 USD
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
140000 USD
CY2016Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
143000 USD
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
101000 USD
CY2016Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
56000 USD
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
294000 USD
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
494000 USD
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
1000 USD
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1000 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2165000 USD
CY2016Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1330000 USD
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5500000 USD
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M2D
CY2016Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3064000 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2799000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
111000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-361000 USD
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-80000 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1476000 USD
CY2015Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-38000 USD
CY2016Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-40000 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-162000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18000 USD
CY2015Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-59000 USD
CY2016Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-213000 USD
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
10000 USD
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
60000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89081000 USD
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82920000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6655000 USD
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4816000 USD
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
101000 USD
CY2016Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
56000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
139000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4327000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-615000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
90000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13506000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9956000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-14758000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-9589000 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
59000 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
67000 USD
CY2016Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2015Q2 vtl Maximum Aggregate Offering Price Of Securities
MaximumAggregateOfferingPriceOfSecurities
200.0 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
9656000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14817000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9656000 USD
CY2015Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
225000 USD
CY2016Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
217000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
431000 USD
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
333000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
184000 USD
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
253000 USD
CY2015Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
163000 USD
CY2016Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
143000 USD
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
49000 USD
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000 USD
CY2015Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2016Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
30000 USD
CY2015Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
280000 USD
CY2016Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
75000 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
674000 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
125000 USD
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1139000 USD
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1044000 USD
CY2015Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32100000 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4325000 USD
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4300000 USD
CY2015Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 USD
CY2016Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
2000 USD
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
139000 USD
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11869000 USD
CY2016Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11927000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3809000 USD
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3428000 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11753000 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6857000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
533000 USD
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
319000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202856000 USD
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212444000 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
803000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
998000 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
345486 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2771815 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.64
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
4896 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
16.74
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
30185 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.87
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.04
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8998083 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3716520 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3733711 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.76
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.76
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8761671 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3644575 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.73
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.92
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.97
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5812571 USD
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M11D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M12D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y4M28D
CY2015Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5.50
CY2015Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6272727 shares
CY2016Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
499000 shares
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8098 shares
CY2015Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34500000 USD
CY2016Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4500000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
82325000 USD
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
78048000 USD
CY2016Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23972599 shares
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30563088 shares
CY2015Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
2675000 USD
CY2016Q1 vtl Accrued Clinical Costs
AccruedClinicalCosts
2125000 USD
CY2016Q1 vtl Cash Equivalents Investments Maturity Period
CashEquivalentsInvestmentsMaturityPeriod
P3M
CY2015Q1 vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
0 USD
CY2016Q1 vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
65000 USD
CY2016Q1 vtl Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
0 USD
CY2016Q1 vtl Maximum Aggregate Offering Price Of Securities
MaximumAggregateOfferingPriceOfSecurities
161000000 USD
CY2015Q4 vtl Underwriting Discounts And Commissions Expenses In Period
UnderwritingDiscountsAndCommissionsExpensesInPeriod
2100000 USD
CY2016Q1 vtl Underwriting Discounts And Commissions Expenses In Period
UnderwritingDiscountsAndCommissionsExpensesInPeriod
134000 USD
CY2015Q4 vtl Maximum Aggregate Offering Price Of Securities
MaximumAggregateOfferingPriceOfSecurities
165500000 USD
CY2016Q1 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
70500000 USD
CY2015Q2 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
75000000 USD
CY2015Q4 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
75000000 USD
CY2015Q2 vtl Maximum Number Of Common Shares That Can Be Issued By Certain Stockholders Under Shelf Registration Statement
MaximumNumberOfCommonSharesThatCanBeIssuedByCertainStockholdersUnderShelfRegistrationStatement
2500000 shares
CY2015Q1 vtl Release Of Repurchase Liability For Stock Options Shares Vested During Period
ReleaseOfRepurchaseLiabilityForStockOptionsSharesVestedDuringPeriod
26000 USD
CY2016Q1 vtl Release Of Repurchase Liability For Stock Options Shares Vested During Period
ReleaseOfRepurchaseLiabilityForStockOptionsSharesVestedDuringPeriod
23000 USD
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001628280-16-015949-index-headers.html Edgar Link pending
0001628280-16-015949-index.html Edgar Link pending
0001628280-16-015949.txt Edgar Link pending
0001628280-16-015949-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-033116xexhibit311.htm Edgar Link pending
vtl-033116xexhibit312.htm Edgar Link pending
vtl-033116xexhibit321.htm Edgar Link pending
vtl-033116xexhibit322.htm Edgar Link pending
vtl-20160331.xml Edgar Link completed
vtl-20160331.xsd Edgar Link pending
vtl-20160331_cal.xml Edgar Link unprocessable
vtl-20160331_def.xml Edgar Link unprocessable
vtl-20160331_lab.xml Edgar Link unprocessable
vtl-20160331_pre.xml Edgar Link unprocessable
vtl-33116x10q.htm Edgar Link pending